Details of the Drug
General Information of Drug (ID: DME81IY)
Drug Name |
Succimer
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Succimer; meso-2,3-Dimercaptosuccinic acid; 304-55-2; DMSA; (2R,3S)-rel-2,3-Dimercaptosuccinic acid; meso-Dimercaptosuccinic acid; Chemet; Dim-sa; Succimerum; Succimero; Dimercaptosuccinic acid; Succimerum [INN-Latin]; Succimero [INN-Spanish]; (R*,S*)-2,3-Dimercaptobutanedioic acid; Butanedioic acid, 2,3-dimercapto-, (2R,3S)-rel-; UNII-DX1U2629QE; Succimer [USAN:INN:BAN]; HSDB 6783; EINECS 206-155-2; Ro 1-7977; BRN 1725150; DX1U2629QE; CHEBI:63623; Butanedioic acid, 2,3-dimercapto-, (R*,S*)-; meso-2,3-Dimercaptobernsteinsaeure
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 182.2 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 0.1 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 4 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | |||||||||||||||||||
ADMET Property | ||||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Transporter (DTP) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
---|---|---|---|---|---|
2 | FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41. | ||||
3 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
4 | MRP2 involvement in renal proximal tubular elimination of methylmercury mediated by DMPS or DMSA. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):10-7. | ||||
5 | Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7. | ||||
6 | Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61. | ||||
7 | Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207. | ||||
8 | Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114. | ||||
9 | Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8. | ||||
10 | Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55. | ||||
11 | Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8. | ||||
12 | Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. | ||||
13 | Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63. | ||||
14 | Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727. | ||||